ArticleBritish journal of clinical pharmacology2026
Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study.
Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study.British journal of clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
aimIn the GENESECT study, no significant gemcitabine (GEM) metabolism-related germline genetic polymorphisms (GPs) were identified because approximately 70% of patients received combination therapy with nab-paclitaxel, which has metabolic pathways different from GEM. The present study was a sub-analysis including only GEM monotherapy patients.
methodsOf 159 patients analysed in the GENESECT study, only GEM-monotherapy patients were selected. The endpoints included carbohydrate antigen 19-9 (CA19-9) response (reduction ≥ 50% from the pretreatment level at 8 weeks), progression-free survival (PFS), and overall survival (OS) in relation to GPs. Analysed genes included those encoding GEM transporters and metabolic enzymes (SLC29A1, ABCC5, CDA, DCK, RRM1/2) and a tumour cell proliferation enzyme (COX-2). Screening and significance levels were set at 10% (univariable) and 5% (multivariable), respectively.
resultsData for 50 patients were analysed. Genotype AA of ABCC5 1146A>G (rs7636910) showed a higher CA19-9 response rate than AG/GG (52.9% vs. 21.2%, p = 0.023) and remained significant in multivariable analysis (odds ratio: 6.255, p = 0.014). It also tended to be associated with longer PFS, but not significantly (hazard ratio [HR]: 0.464, p = 0.074). By contrast, although CA19-9 responses were not significantly associated with DCK -1205T>C (rs4694362), the TT/TC genotype was significantly associated with prolonged PFS compared with CC (median 127 vs. 48 days, p = 0.002), and this association remained significant in multivariable analysis (HR: 0.153, p = 0.028). No GPs were significantly associated with OS.
conclusionABCC5 and DCK might be related to the efficacy of GEM treatment, but further research is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.